Company Overview

Angiocrine Bioscience, Inc. is an innovative cellular therapy company committed to changing the face of curative treatments through our E-CEL® technology. We are transforming the standards of medical practice through our rationally designed, inspired by nature, therapeutic platforms designed to drive stem cell renewal in a variety of disease settings.

Angiocrine’s core technology is licensed from Weill Cornell Medicine and was invented and developed by Professor Shahin Rafii, M.D. His work related to Angiocrine technology has been published in numerous peer-reviewed journals, including Cell Stem Cell, Nature, Cell and Blood.